Background and objectives
Introduction consulted in forming the search strategies, which consisted of search terms relating to FQs, AEs, health service use and costs. The Web of Science -database search included several conference papers, which could be used to find unpublished literature and reduce publication bias. Finally, literature references of the included articles were sourced to identify potentially relevant articles. The search strategy for Medline can be found in S1 File. In this systematic review, AEs are defined as medical occurrences temporally associated with the use of a medicinal product, but not necessarily causally related. A serious adverse event, on the other hand, is defined as any untoward medical occurrence that at any dose either results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability or incapacity. [14] Health service use is referred to as services provided to individuals or communities by health service providers for the purpose of promoting, maintaining, monitoring or restoring health [15] . Costs presented in this study comprise resources consumed due to health service use.
Study selection
References identified in the literature search were imported to reference management software (Mendeley) and duplicates were removed. Only references that met previously fixed PICOS (patients, intervention, control, outcome, setting) [16] criteria, were included in the review. There were no limitations concerning publication year. The PICOS framework is depicted in Table 1 .
Both reviewers (LK, KV) individually screened the articles based on title and excluded distinctly irrelevant references such as literature regarding topical ophthalmic FQs. A third author (MB) was available to resolve possible discrepancies. The remaining articles were screened based on abstracts and full texts. The number of identified, included and excluded references are depicted in the flow chart.
Data collection
The data of the included articles was extracted into two spread sheets (Microsoft Excel). The usefulness of the tables was tested with a total of eight articles, after which minor adjustments were made regarding the reporting of fatalities. Both reviewers (LK, KV) filled in both tables independently. The first table contains characteristics of the included studies, such as authors, publication years, aims, patient details, study designs, durations, follow-ups, funding details and publications. The second table summarizes results covering specifics of the fluoroquinolone associated with the adverse event, adverse event types, health service use, length of hospital stay, AE costs and possible fatalities. In order to improve comparability, all the reported costs were converted to euro by using the exchange rate of the European Central Bank and 
Quality assessment
The quality of the included studies was assessed according to the STROBE checklist for observational studies. [19] The studies were awarded scores, which are presented in percentages. Two reviewers (LK, KV) assessed the quality of the included studies independently. The level of agreement between the reviewers was 93%.
Results

Search results
In all, 4,454 unique references were identified in the literature search (Fig 1) . Screening based on titles excluded 4,217 references. Two hundred and twenty full-text articles did either not meet the inclusion criteria (n = 208 studies), were found to be duplicates (n = 8) or lacked an English language full-text (n = 4). After two additional studies were found in literature references, a total of 19 studies were included in this systematic review. The list of the excluded articles is displayed in S2 File. were identified from one study [25] . The average age of all total sample was 60,8 years and 50,71% were men. Only one study explicitly involved a cohort of patients with comorbidities (diabetes). [26] The characteristics of the included studies are summarized in Table 2 .
Study characteristics
Health service use
Although the search covered all AEs related to FQs, the AEs depicted in the included studies can mostly be defined as serious, since hospitalization was the most frequently reported AErelated health service use (17 studies [20] [29] ) and the disparity between estimations was significant. The cost of an AE-related episode varied in this systematic review between 140 and 18,252 € and there was also considerable variation among AE episodes within some individual studies. Llop, for example, evaluated the cost of an average FQ-related AE episode to be 4,528±18,252 € [25] . In this systematic review, the highest reported health care costs were associated with CDAD, and costs associated with other AEs were not specified. In four studies, costs were evaluated from the perspective of the hospital [29] specifically stated that costs consist of direct hospital costs. Llop et.al. [25] did not specify cost details beyond costs associated with AEs and retreatment. None of the included studies reported travel or time costs, indirect costs or specified the payer. [35] and linked to an epileptic seizure, urticarial lesion, fixed drug effect, exfoliative dermatitis, angioedema and photodermatitis (PD).
In the included studies, norfloxacin and ofloxacin were associated with the least reports of health service use and costs. Conversely, levofloxacin and ciprofloxacin, the most frequently considered FQs, appeared to be connected to the most AEs, health service use and costs. Health service use and health service costs associated with FQ-related AEs are depicted in Table 3 .
The quality of the included studies
The results of the quality assessment are illustrated in Fig 2. The included studies scored an average 19.74 and median 20 (range 10 and 27) points out of 34 total points. The weighted average rating was 65% (range 36-84%). Although the scores are relatively high, some inadequacies were apparent in reporting. Only six studies described efforts to address potential sources of bias ([20] [37] ). The case-controlled observational studies all reported the source of research funding but otherwise there was no difference in the results of the quality assessment regarding study design. The fulfillment of the STROBE checklist items is portrayed in S1 Table.
Discussion
The aim of this systematic review was to identify health service use and costs associated with FQ-related AEs. To date, research concentrating on costs associated with drug-related AEs remains scarce. As far as we know, the economic impacts of any FQ-related AEs have previously not been examined in a systematic review. Due to the substantial gap in published literature, we were unable to examine many serious and costly FQ-related AEs, such as neuropsychiatric AEs, QT interval prolongation, aortic aneurysm and tendinopathy in this review. There was considerable heterogeneity among the included studies. The most variation was associated with population sample sizes (n = 33-1,277,248) and study duration (4 weeks-22 years) as well as AEs considered. Although randomized controlled trials (RCTs) were not excluded from the literature search, all the included studies were observational. Observational studies may pick up on AEs not observed in RCTs, which might be due to several factors. RCTs frequently exclude patients who are most vulnerable to AEs, such as the elderly and patients with comorbidities. In addition, sample sizes are in many cases smaller and follow-up periods often shorter in RCTs than in observational studies. Of the 19 studies included in the review, five were case-controlled, in order to explicitly observe risk rates of AEs associated with FQs. Even then, the number of FQ-related AEs assessed in the included studies in proportion to the population size was small, which could mean that all FQ-related AEs were not [36] Levo, cipro N = 32 Diarrhea (levo n = 17, cipro n = 4), pseudomembranous colitis (levo n = 2), altered mental status (levo n = 1), rash (levo n = 1, cipro n = 1), thrush (levo n = 4), hepatitis (cipro n = 1), fever (cipro n = 1) Norfloxacin, on the other hand, was only linked to two cases of hepatitis. These data do not allow comparisons across FQs and drawing of definite conclusions relating to health service use and costs associated with levofloxacin, ciprofloxacin, moxifloxacin, norfloxacin and ofloxacin. Levofloxacin and ciprofloxacin were considered in 12 studies, including extremely large studies, and norfloxacin in only one. Therefore, the number of AEs associated with specific FQs reported in the studies is related to the utilization of the FQ and not necessarily to the toxicity. At present ciprofloxacin followed by levofloxacin are the most consumed FQs globally [39] [40] . Previous research has shown that the safety profiles of the FQs included in this systematic review are similar to each other [1] . In this systematic review, hospitalizations and ED visits were the main health service use outcomes associated with AEs. Outpatient visits to primary care facilities were not reported in FQ-related AEs resulting in health service use and costs the included studies, although it is likely that most AEs are diagnosed and treated in primary care, if recognized as FQ-related at all. According to prior research by Magdelijns et.al., hospitalizations, specifically long stays in hospital, are the leading cost drivers in health service use. Hospitalizations were estimated to cause approximately 77% of direct health care costs associated with AEs in the Netherlands [41] .
Reported FQ-related AE-costs varied between 140 and 18,252€ per AE episode. CDAD was associated with the largest amount of health service use, longest stays in hospital and, thus, the highest reported costs of AEs considered. Mean CDAD-related length of stays were up to 45 days. Since the emergence of the epidemic Clostridium difficile ribotype 027 clone, CDAD has become more prevalent, severe and more difficult to treat, due to resistance to many antimicrobial agents [42] . The included studies took only into account the direct treatment costs, which does not represent the total costs of a FQ-related AE episode. Evaluating all AE-triggered costs, regardless of who they fall on, would reflect a more accurate assessment. However, as described in Table 2 , the aims of the included studies did not involve examining health service use or costs. Therefore, both health service use and costs were addressed in a cursory manner and were likely underestimated. In the five studies that did report costs ( [23] [25] [32] [35] [29]), they proved difficult to compare. Costs relating to healthcare systems, diagnostic methods and treatment protocols differ significantly depending on the origin of the study and the AEs considered. In addition, the severity of the reported FQ-related AEs may have fluctuated and resulted in diverse health service use and costs. AE-related costs, when reported, lack adequate transferability. Conversely, health service use and length of hospital stay are outcomes that can be more effectively compared and transferred, regardless of the origin of the study. Even here, temporal, geographical and payer differences may lead to disparities in these metrics for similar AEs.
Limitations of this systematic review include confining the literature search to full English language texts. However, the risk of lost key findings is minor due to the paucity of nonEnglish texts excluded from the review. In addition, we excluded studies with pediatric patients, though inclusion could have led to added information about health service use and costs. The use of FQs in children continues to be limited or restricted. Although studies have described the majority of FQ-related AEs in pediatric patients as temporary and reversible [43] , real-world safety data continue to be scarce. We acknowledge that the use of STROBE checklist for observational studies is not recommended for assessing the methodological quality of studies. There is a distinct deficiency of reliable, comprehensive and validated tools for the quality assessment of observational studies. We did not exclude any studies due to poor quality and therefore using STROBE did not introduce bias into this systematic review. Additionally, there is a lack of guidelines and definitions regarding data quality, which is not addressed in quality assessments. This could potentially cause bias. The shortage of existing research relating to health service use and costs associated with FQ-related AEs and the incomplete nature of AEs considered in those that do report these, account for the largest limitation of this systematic review. Funding, in addition to the undetection and underreporting of AEs are issues that can restrict and direct studies. Present means and resources available to allow independent AEresearch are poor.
Conclusions
Because of the wide clinical use of FQs, in particular serious FQ-related AEs can have substantial economic implications, in addition to imposing potentially long-lasting health complications for patients. Better-quality reporting and additional published data on health service use and costs associated with AEs are both necessary and overdue.
